Targeting of the renin-angiotensin system by antisense gene therapy: A possible strategy for the long-term control of hypertension

Journal of Hypertension

Volumn 18, Issue 4, 2000, Pages 353-362

  Raizada, Mohan K ^a,c   Francis, Sharon C ^a   Wang, Hongwei ^a   Gelband, Craig H ^a   Reaves, Phyllis Y ^a   Katovich, Michael J ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antisense; AT1 receptor; Gene therapy; Hypertension; Renal and cardiac pathophysiology; Renin angiotensin system; Viral vectors

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; CHIMERIC PROTEIN; COMPLEMENTARY DNA; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; GREEN FLUORESCENT PROTEIN; LIGAND; LIPOSOME; MIFEPRISTONE; OLIGONUCLEOTIDE; RAPAMYCIN; RENIN; TETRACYCLINE; VIRUS VECTOR;

ADENOVIRUS; ADVERSE DRUG REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOVASCULAR DISEASE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; HYPERTENSION; LENTIVIRINAE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROVIRUS; REVIEW; TRANSGENE;

EID: 0034034173     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. 1 Fyhrquist F, Metsarinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens 1995; 9(Suppl 5):S19-S24.
2. 2 Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 1999; 10(Suppl 12):S258-S265.
3. 3 May CN, McAllen RM. Baroreceptor-independent renal nerve inhibition by intracerebroventricular angiotensin II in conscious sheep. Am J Physiol 1997; 273:R560-R567.
4. 4 Krieger JE, Dzau VJ. Molecular biology of hypertension. Hypertension 1991; 18(3 Suppl):13-117.
5. 5 Marche P, Herembert T, Zhu DL. Molecular mechanisms of vascular hypertrophy in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 1995; 22(Suppl 1):S114-S116.
6. 6 Orlowski JM. Mechanisms of renal hypertension and renal contribution to primary hypertension. Steroids 1993; 58:588-593.
7. 7 Montgomery HE, Kiernan LA, Whitworth CE, Fleming S, Unger T, Gohlke P, et al. Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J Hypertens 1998; 16:635-643.
8. 8 Tomita N, Morishita R, Higaki J, Aoki M, Nakamura Y, Mikami H, et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 1995; 26:131-136.
9. 9 Yamazaki T, Yazaki Y. Role of tissue angiotensin II in myocardial remodeling induced by mechanical stress. J Hum Hypertens 1999; 12(Suppl 1):S43-S47.
10. 10 Chao J, Zhang JJ, Lin KF, Chao L. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 1998; 54:1250-1260.
11. 11 Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension 1999; 33:219-224.
12. 12 Lu D, Raizada MK. Delivery of angiotensin II type 1 receptor antisense inhibits angiotensin action in neurons from hypertensive rat brain. Proc Natl Acad Sci USA 1995; 92:2914-2918.
13. 13 Yayama K, Wang C, Chao L, Chao J. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 1998; 3:1104-1110.
14. 14 Martens JR, Reaves PY, Lu D, Katovich MJ, Berecek KH, Bishop SP, et al. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc Natl Acad Sci USA 1998; 95:2664-2669.
15. 1R mRNA antisense. Hypertension 1997; 29:374-380.
16. 1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998; 20:205-221.
17. 17 Weber MA. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. J Hypertens 1997; 15(Suppl):S31-S36.
18. 18 Mombouli JV. ACE inhibition, endothelial function and coronary artery lesions: role of kinins and nitric oxide. Drugs 1997; 54(Suppl 5):12-22.
19. 19 Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the antifibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51:164-172.
20. 20 Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95:995-1001.
21. 21 Makino N, Sugano M, Ohtsuka S, Sawada S. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 1998; 31:1166-1170.
22. 1R-AS) in the adult spontaneously hypertensive rat (SHR). Circulation 1998; 98:1320.
23. 23 Gelband, CH, Reaves PY, Evans J, Wang H, Katovich MJ, Raizada MK. Angiotensin II type 1 receptor antisense gene therapy prevents altered renal vascular calcium homeostasis in hypertension. Hypertension 1999; 33:360-365.
24. 24 Iyer SN, Lu D, Katovich MJ, Raizada MK. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense. Proc Natl Acad Sci USA 1996; 93:9960-9965.
25. 25 Lu D, Raizada MK, Iyer S, Reaves P, Yang H, Katovich MJ. Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension 1997; 30:363-370.
26. 1 -Rs and angiotensin II action in astroglial and neuronal cells in primary cultures from the brain. Proc Natl Acad Sci USA 1995; 92:1162-1166.
27. 1 receptor antisense in neurons and SMC. Am J Physiol 1998;274:H719-H727.
28. 28 Guntaka, RV, Swamynathan SK. Retroviral vectors for gene therapy. Ind J Exp Biol 1998; 36:539-545.
29. 29 Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 1998; 80:35-47.
30. 30 Channon KM, George SE. Improved adenoviral vectors: cautious optimism for gene therapy. Quart J Med 1997; 90:105-109.
31. 31 Kovesdi I, Brough DE, Bruder JT, Wickham TJ. Adenoviral vectors for gene transfer. Curr Opin Biotechnol 1997; 8:583-589.
32. 32 Chao JJ, Zhang J, Lin KF, Chao L. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 1998; 9:21-31.
33. 33 Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther 1998; 9:1429-1438.
34. 34 Lin KF, Chao J, Chao L. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension 1995; 26:847-853.
35. 35 Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther 1995; 2:357-362.
36. 36 Hallek M, Wendtener CM. Recombinant adeno-associated virus (rAAV) vectors for somatic gene therapy; recent advances and potential clinical applications. Cytosine Mol Ther 1996; 2:69-79.
37. 37 Langer JC, Klotman ME, Hanss B, Tulchin N, Bruggeman LA, Klotman PE, et al. Adeno-associated virus gene transfer into renal cells: potential for in vivo gene delivery. Exp Nephrol 1998; 6:189-194.
38. 38 Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93:11382-11388.
39. 39 Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997; 389:239-242.
40. 40 Regan CP, Bishop SP, Berecek KH. Early, short-term treatment with captopril permanently attenuates cardiovascular changes in spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19:1161-1177.
41. 41 Wang Y, DeMayo J, Tsai SY, O'Malley BW. Ligand inducible and liver specific target gene expression in transgenic mice. Nat Biotechnol 1997; 15:239-243.
42. 42 Huang CJ, Spinella F, Nazarian R, Lee MM, Dopp JM, de Vellis J. Expression of green fluorescent protein in oligodendrocyctes in a time-and level-controllable fashion with a tetracycline regulated system. Mol Med 1999; 5:129-137.
43. 43 Haberman RP, McCown TJ, Samulski RJ. Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther 1998; 5:1604-1611.
44. 44 Bader M, Ganten D. Transgenic rats: tools to study the function of the renin-angiotensin system. Clin Exp Pharmacol Physiol 1996; 3(Suppl):S81-S87.
45. 45 Engler S, Paul M, Pinto YM. The TGR(mRen2)27 transgenic rat model of hypertension. Regul Pept 1998; 77:3-8.
46. 46 Pinto-Sietsma SJ, Paul M. Transgenic rats as models for hypertension. J Hum Hypertens 1997; 11:577-581.
47. 47 Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998; 39:77-88.
48. 1-receptor mRNA in brain and blood. Hypertension 1998; 31:1317-1323.